公开(公告)号：US11814437B2

公开(公告)日：2023-11-14

申请号：US17938523

申请日：2022-10-06

Applicant: GENMAB A/S

Inventor： David Satijn ,  Patrick Engelberts ,  Kristel Kemper ,  Esther C. W. Breij ,  Simone Oostindie ,  Farshid Alemdehy

IPC: C07K16/28 ,  A61P35/00 ,  C12N15/63

CPC classification number: C07K16/2878 ,  A61P35/00 ,  C07K16/2809 ,  C12N15/63 ,  C07K2317/31 ,  C07K2317/526 ,  C07K2317/565

Abstract: The invention relates to multispecific antibodies binding to CD3 and CD30. The invention further provides pharmaceutical compositions comprising antibodies of the invention, nucleic acids encoding the antibodies, host cells that produce the antibodies, methods of producing the antibodies and uses of the antibodies, in particular for cancer therapy.

公开(公告)号：US20230357440A1

公开(公告)日：2023-11-09

申请号：US18025205

申请日：2021-09-10

Applicant: GENMAB A/S

Inventor： Brian ELLIOTT ,  Tahamtan AHMADI ,  Christopher W.L. CHIU ,  Esther C.W. BREIJ

IPC: C07K16/46 ,  A61P35/00

CPC classification number: C07K16/468 ,  A61P35/00 ,  C07K2317/565 ,  C07K2317/31 ,  C07K2317/24 ,  C07K2317/52

Abstract: Provided are methods of clinical treatment of follicular lymphoma (for example, relapsed and/or refractory follicular lymphoma) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimens of rituximab and bendamustine.

公开(公告)号：US20230355753A1

公开(公告)日：2023-11-09

申请号：US18025206

申请日：2021-09-10

Applicant: GENMAB A/S

Inventor： Brian ELLIOTT ,  Tahamtan AHMADI

IPC: A61K39/395 ,  A61P35/00 ,  A61K31/573 ,  A61K31/7068 ,  A61K31/282

CPC classification number: A61K39/3955 ,  A61P35/00 ,  A61K31/573 ,  A61K31/7068 ,  A61K31/282 ,  A61K2039/545

Abstract: Provided are methods of clinical treatment of diffuse large B-cell lymphoma (DLBCL) (e.g., relapsed and/or refractory DLBCL eligible for autologous stem cell transplant) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimen of R-DHAX/C (rituximab, dexamethasone, cytarabine, and oxaliplatin/carboplatin).

公开(公告)号：US20230303693A1

公开(公告)日：2023-09-28

申请号：US18160391

申请日：2023-01-27

Applicant: GENMAB A/S

Inventor： Christopher W. L. CHIU ,  Mariana Cota STIRNER ,  Minh H. DINH ,  IIiana Edith SZAFER-GLUSMAN

IPC: C07K16/28 ,  A61P35/00 ,  A61K47/68 ,  A61K39/395 ,  A61K31/675 ,  A61K31/704 ,  A61K31/573

CPC classification number: C07K16/2809 ,  A61P35/00 ,  A61K47/6811 ,  A61K47/6867 ,  A61K39/3955 ,  A61K31/675 ,  A61K31/704 ,  A61K31/573 ,  C07K16/2887 ,  A61K2039/507

Abstract: Provided are methods of clinical treatment of diffuse large B-cell lymphoma (DLBCL) (e.g., previously untreated DLBCL) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with Pola-R-CHP (polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone).

公开(公告)号：US20230263902A1

公开(公告)日：2023-08-24

申请号：US18010783

申请日：2021-06-29

Applicant: Genmab A/S

Inventor： Reshma A. RANGWALA

IPC: A61K47/68 ,  A61P35/00 ,  A61K9/00

CPC classification number: A61K47/6803 ,  A61K47/6849 ,  A61P35/00 ,  A61K9/0019

Abstract: The invention provides methods and compositions for treating cancer, such as advanced cervical cancer, in a subject, such as by the administration of antibody-drug conjugates that bind to tissue factor (TF). The invention also provides articles of manufacture and compositions comprising said antibody drug-conjugates that bind to TF for use in treating cancer (e.g., advanced cervical cancer).

公开(公告)号：US20230227495A1

公开(公告)日：2023-07-20

申请号：US17939736

申请日：2022-09-07

Applicant: Genmab A/S

Inventor： Michael GRAMER ,  Amitava Kundu ,  Ewald T. J. Van Den Bremer ,  Muriel Van Kampen ,  Patrick Priem ,  Aran Frank Labrijn ,  Joyce I. Meesters ,  Joost J. Neijssen ,  Janine Schuurman ,  Paul Parren ,  Patrick Van Berkel ,  Werner L. Vos ,  Amout F. Gerritsen

IPC: C07K1/113 ,  C07K16/28 ,  C07K16/46

CPC classification number: C07K1/1133 ,  C07K16/2863 ,  C07K16/2887 ,  C07K16/468 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/41 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/53 ,  C07K2317/55 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/90

Abstract: The present invention relates to an in vitro method for production of heterodimeric proteins.

公开(公告)号：US20230027495A1

公开(公告)日：2023-01-26

申请号：US17775279

申请日：2020-11-06

Applicant: Genmab A/S ,  MSD International GmbH

Inventor： Reshma Abdulla RANGWALA ,  Esther C.W. BREIJ ,  Sandra VERPLOEGEN ,  Oyewale O. ABIDOYE ,  Leonardo Viana NICACIO ,  Anthony CAO ,  Shyra GARDAI

IPC: A61K47/68 ,  C07K16/28 ,  C07K16/36 ,  A61P35/00

Abstract: The invention provides an anti-PD-1 antibody comprising the complementary determining regions (CDRs) of pembrolizumab in combination with an antibody-drug conjugate that binds to tissue factor (TF) comprising monomethyl auristatin E and the CDRs of tisotumab (e.g., tisotumab vedotin) and their use in methods of treating cancer, such as breast cancer and cervical cancer. The invention also provides compositions and kits comprising the anti-PD-1 antibody comprising the CDRs of pembrolizumab and the antibody-drug conjugate that binds to TF comprising monomethyl auristatin E and the CDRs of tisotumab (e.g., tisotumab vedotin) for use in treating cancer, such as breast cancer and cervical cancer.

公开(公告)号：US11492371B2

公开(公告)日：2022-11-08

申请号：US16426647

申请日：2019-05-30

Applicant: GENMAB A/S

Inventor： Michael Gramer ,  Amitava Kundu ,  Ewald T. J. Van Den Bremer ,  Muriel Van Kampen ,  Patrick Priem ,  Aran Frank Labrijn ,  Joyce I. Meesters ,  Joost J. Neijssen ,  Janine Schuurman ,  Paul Parren ,  Patrick Van Berkel ,  Werner L. Vos ,  Arnout F. Gerritsen

IPC: C07K1/113 ,  C07K16/28 ,  C07K16/46

Abstract: The present invention relates to an in vitro method for production of heterodimeric proteins.

公开(公告)号：US11359015B2

公开(公告)日：2022-06-14

申请号：US15744317

申请日：2016-07-14

Applicant: GENMAB A/S

Inventor： Rik Rademaker ,  Isil Altintas ,  Patrick Engelberts ,  Janine Schuurman ,  Paul Parren

IPC: C07K16/00 ,  C07K16/28 ,  C07K16/32 ,  A61K39/00

Abstract: The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.

公开(公告)号：US20220144964A1

公开(公告)日：2022-05-12

申请号：US17559938

申请日：2021-12-22

Applicant: GENMAB A/S

Inventor： Brian ELLIOTT ,  Tahamtan AHMADI ,  Christopher W. L. CHIU ,  Esther C. W. BREIJ ,  Ida HIEMSTRA ,  Maria N. JURE-KUNKEL

IPC: C07K16/28 ,  A61K31/454

Abstract: Provided are methods of clinical treatment of follicular lymphoma (for example, relapsed and/or refractory follicular lymphoma) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimens of rituximab and lenalidomide.